Max Healthcare Institute Limited (MAXHEALTH:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Max Healthcare Institute Limited stock forecast from 0 analysts, the average analyst target price for Max Healthcare Institute Limited is not available over the next 12 months. Max Healthcare Institute Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Max Healthcare Institute Limited is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Max Healthcare Institute Limited’s stock price was INR 778.10. Max Healthcare Institute Limited’s stock price has changed by -9.98% over the past week, +6.52% over the past month and +67.73% over the last year.
No recent analyst target price found for Max Healthcare Institute Limited
No recent average analyst rating found for Max Healthcare Institute Limited
Company Overview Max Healthcare Institute Limited
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including bariatric surgery/metabolic, bone marrow transplant, cancer/oncology, cardiac science, endocrinology and diabetes, eye care, gastroenterology, hepatology and endoscopy, kidney transplant, laparoscopic, liver transplant, neuro science, orthopedics, robotic surgery, urology, and vascular surgery. The company provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic services to patients outside its network of hospitals through various channels comprising third-party hospital laboratory management. It operates through a network of healthcare facilities, including hospitals and medical centres in Delhi and National Capital Region, Maharashtra, Punjab, Uttar Pradesh, and Uttarakhand. The company is based in Gurugram, India. Read Less
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including bariatric surgery/metabolic, bone marrow transplant, cancer/oncology, cardiac science, endocrinology and diabetes, eye care, gastroenterology, ...Read More
Frequently Asked Questions About Max Healthcare Institute Limited (MAXHEALTH:NSE) Stock
Stock Target Advisor's fundamental analysis for Max Healthcare Institute Limited's stock is Slightly Bullish .
MAXHEALTH:NSE stock's dividend yield is 0.11%.
Our analysis grades MAXHEALTH:NSE stock's dividend yield at F. This means that MAXHEALTH:NSE stock's dividend yield is above 13% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this MAXHEALTH:NSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on MAXHEALTH:NSE's stock to indicate what its average analyst target is.
MAXHEALTH:NSE stock's Price/Earning ratio is 80.00.
Our analysis grades MAXHEALTH:NSE stock's Price / Earning ratio at F. This means that MAXHEALTH:NSE stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this MAXHEALTH:NSE may be a overvalued for its sector.
The last closing price of MAXHEALTH:NSE's stock was INR 778.10.
The most recent market capitalization for MAXHEALTH:NSE is INR 846.00B.
Unfortunately we do not have enough analyst data on MAXHEALTH:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Max Healthcare Institute Limited's stock.
As per our most recent records Max Healthcare Institute Limited has 15,000 Employees.
Max Healthcare Institute Limited's registered address is Capital Cyberscape, Gurugram, India, 122011.
You can get more information about it from Max Healthcare Institute Limited's website at https://www.maxhealthcare.in.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MAXHEALTH:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
